Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials

Abstract

No systematic review or meta-analysis using a hard outcome has been conducted on the role of benzodiazepines for generalized anxiety disorder (GAD). The objective of this study was to assess the effectiveness and efficacy of benzodiazepines in the treatment of GAD based on trial drop-out rates. We used a systematic review of randomized controlled trials that compared any of the three best established benzodiazepines (diazepam, Lorazepam and aLprazolam) against placebo. Our primary outcome for effectiveness was withdrawal for any reason. Our secondary outcome tapping efficacy was withdrawal due to lack of efficacy, and that tapping side effects was withdrawals due to adverse events.

We included 23 trials. Pooled analysis indicated less risk of treatment discontinuation due to lack of efficacy for benzodiazepines, compared to placebo, relative risk (RR) 0.29 (95% CI 0.18—0.45; p < 0.00001). Nevertheless, pooled analysis showed no conclusive results for risk of all-cause patient discontinuation, RR 0.78 (95% CI 0.62—1.00; p = 0.05). Meta-regression model showed that 74% of the variation in logRR across the studies was explained by year of publication (p <0.001).

This systematic review did not find convincing evidence of the short-term effectiveness of the benzodiazepines in the treatment of GAD. On the other hand, for the outcome of efficacy, this review found robust evidence in favour of benzodiazepines. Due to the heterogeneity induced by year of publication, three hypotheses are plausibLe when it comes to being able to account for the differences between efficacy and effectiveness observed in the outcomes (publication bias, quality of the trial literature and a non-differential response to the placebo effect).

Keywords

generalized anxiety disorder benzodiazepines systematic review clinical trial

Get full access to this article

View all access options for this article.

References

Allgulander C. , Bandelow B. , Hollander E. , Montgomery S A. , Nutt D J. , Okasha A. , Pollack M H. , Stein D J. , Swinson R P. (2003) WCA recommendations for the long-term treatment of generalized anxiety disorder . CNS Spectr 8(8 Suppl 1): 53—61

Barker M.J. , Greenwood K.M. , Jackson M. , Crowe S.F. (2004) Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS .Drugs 18: 37—48

Bordchart M. (1999) Review of the clinical pharmacology and use of benzodiazepines . J Perianesth Nurs 14: 65—72

Copas J. , Shi J.Q. (2000) Meta-analysis, funnel plots and sensitivity analysis . Biostatistics. 1: 247—262

Deeks J.J. , Altman D.G. (2001) Effect measures for meta-analysis of trials with binary outcomes. In Egger M , Davey Smith G , Altman D H (eds), Systematic Reviews in Health Care: Meta-analysis in Context. BMJ Publication Group, London

DerSimonian R. , Laird N. (1986) Meta-analysis in clinical trials . Control Clin Trials 7: 177—188

Dubben H H. , Beck-Bornholdt H P. (2005) Systematic review of publication bias in studies on publication bias . Br Med J 331: 433—434

Giacinti L. , Lopez M. , Giordano A. (2006) Clinical trials . Front Biosci 11: 2918—2923

Goodman W.K. (2004) Selecting pharmacotherapy for generalized anxiety disorder. Journal of Clinical Psychiatry 65(Suppl 13): 8—13

10.

Gorman J.M. (2003) Treating generalized anxiety disorder. Journal of Clinical Psychiatry 64(Suppl 2): 24—29

11.

Higgins J P T , Thompson S.G. , Deeks J.J. , Altman D.G. (2003) Measuring inconsistency in meta-analysis . Br Med J 327: 557—560

12.

Jüni P. , Altman D.G. , Egger M. (2001) Assessing the quality of controlled clinical trials . Br Med J 323: 42—46

13.

Kessler R C. , DuPont R L. , Berglund P. , Wittchen H U. (1999) Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys . American Journal of Psychiatry 156: 1915—1923

14.

Kessler R.C. , Keller M.B. , Wittchen H.U. (2001) The epidemiology of generalized anxiety disorder . Psychiatric Clinics of North America 24: 19—39

15.

Lieberman J A. , Stroup T S. , McEvoy J P. , Swartz M S. , Rosenheck R A. , Perkins D O. , Keefe R S. , Davis S M. , Davis C E. , Lebowitz B D. , Severe J. , Hsiao J K. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia . New England Journal of Medicine 353: 1209—1223

16.

Mahe V. , Balogh A. (2000) Long-term pharmacological treatment of generalized anxiety disorder. International Clinical Psychopharmacology 15: 99—105

17.

Mantel N. , Haenszel W. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 22: 719—748

18.

Mitte K. , Noack P. , Steil R. , Hautzinger M. (2005) A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder . Journal of Clinical Psychopharmacology 25: 141—150

19.

Moher D. , Schulz K.F. , Altman D.G. (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials . Lancet 357: 1191—1194

20.

Moher D. , Altman D.G. , Schulz K.F. , Elbourne D.R. (2004) Opportunities and challenges for improving the quality of reporting clinical research: CONSORT and beyond . CMAJ. 171: 349—350

21.

Neutel C.I. (1995) Risk of traffic accident injury after a prescription for a benzodiazepine. Annals of Epidemiology 5: 239—244

22.

Neutel C.I. , Hirdes J.P. , Maxwell C.J. , Patten S.B. (1996) New evidence on benzodiazepine use and falls: the time factor. Age and Ageing 25: 273—278

23.

Nutt D. , Argyropoulos S. , Hood S. , Potokar J. (2006) Generalized anxiety disorder: A comorbid disease . European Neuropsychopharmacology 16(Suppl 2): S109—S118

24.

Pollack M.H. , Meoni P. , Otto MW , Simon N. , Hackett D. (2003) Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies . Journal of Clinical Psychopharmacology 23: 250—259

25.

Review Manager (Rev Man) [Computer program]. ( 2003) Versión 4.2 for Windows. The Cochrane Collaboration, Oxford, UK

26.

Rickels K. , Rynn M. ( 2002) Pharmacotherapy of generalized anxiety disorder. Journal of Clinical Psychiatry 63(Suppl 14): 9—16

27.

Rothstein H.R. , Sutton A.J. , Borenstein M. (2005) Publication Bias in Meta-analysis: Prevention, Assessment and Adjustments. John Wiley & Sons Ltd, UK

28.

Rudolph U. (2001) Identification of molecular substrate for the attenuation of anxiety: a step toward the development of better anti-anxiety drugs. Scientific World Journal 1: 192—193

29.

Rynn M.A. , Brawman-Mintzer O. (2004) Generalized anxiety disorder: acute and chronic treatment . CNS Spectr 9: 716—723

30.

Sareen J. , Chartier M. , Paulus M.P. , Stein M.B. (2006) Illicit drug use and anxiety disorders: findings from two community surveys . Psychiatry Research 142: 11—17

31.

Schweizer E. , Rickels K. (1998) Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management . Acta Psychiatr Scand Suppl 393: 95—101

32.

Schulz K.F. , Chalmers I. , Hayes R.J. , Altman D.G. (1995) Dimensions of methodological quality associated with estimates of treatment effects in controlled trials . J Am Med Assoc 273: 408—412

33.

Sharp S.J. , Sterne J A C (1997) Sbe 16: Meta-analysis. STATA . Technical Bulletin 38: 9—14

34.

Stewart S.A. (2005) The effects of benzodiazepines on cognition. Journal of Clinical Psychiatry 66(Suppl 2): 9—13

35.

Struzik L. , Vermani M. , Coonerty-Femiano A. , Katzman M.A. (2004) Treatments for generalized anxiety disorder . Expert Rev Neurother 4: 285—294

36.

Sweetman S. (2004) Martindale: The Complete Drug Reference, 34th edition. Pharmaceutical Press, London : UK

37.

Toma M. , McAlister F A. , Bialy L. , Adams D. , Vandermeer B. , Armstrong P W. (2006) Transition from meeting abstract to full-length journal article for randomized controlled trials . JAMA 295: 1281—1287

38.

Walach H. , Sadaghiani C. , Dehm C. , Bierman D. (2005) The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials—a secondary analysis . BMC Med Res Methodol 5: 26

39.

Wittchen H.U. , Zhao S. , Kessler R.C. , Eaton W.W. (1994) DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Archives of General Psychiatry 51: 355—364